ADC Therapeutics SA (ADCT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ADC Therapeutics SA (ADCT) has a cash flow conversion efficiency ratio of 0.137x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-29.71 Million) by net assets ($-216.38 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see ADC Therapeutics SA market capitalisation for the company's overall valuation and market capitalisation.
ADC Therapeutics SA - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how ADC Therapeutics SA's cash flow conversion efficiency has evolved over time, based on yearly financial data.
ADC Therapeutics SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ADC Therapeutics SA ranked by their cash flow conversion efficiency. See ADC Therapeutics SA (ADCT) debt coverage ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Group Eleven Resources Corp
V:ZNG
|
-0.080x |
|
SRV YHTIOET OYJ
F:B7J1
|
N/A |
|
Bny Mellon Municipal Income Inc
NYSE MKT:DMF
|
0.000x |
|
Bulten AB
ST:BULTEN
|
0.027x |
|
IZMO Limited
NSE:IZMO
|
0.009x |
|
Limes Schlosskliniken AG
XETRA:LIK
|
0.135x |
|
Emmerson Resources Ltd
AU:ERM
|
-0.329x |
|
Hyloris Developmentsen Sa
BR:HYL
|
-0.058x |
Annual Cash Flow Conversion Efficiency for ADC Therapeutics SA (2017–2025)
The table below shows the annual cash flow conversion efficiency of ADC Therapeutics SA from 2017 to 2025. View today's stock price for ADC Therapeutics SA for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-185.83 Million | $-141.17 Million | 0.760x | +24.31% |
| 2024-12-31 | $-202.64 Million | $-123.83 Million | 0.611x | -23.67% |
| 2023-12-31 | $-148.25 Million | $-118.69 Million | 0.801x | +145.99% |
| 2022-12-31 | $79.45 Million | $-138.31 Million | -1.741x | -23.89% |
| 2021-12-31 | $166.09 Million | $-233.38 Million | -1.405x | -179.40% |
| 2020-12-31 | $335.50 Million | $-168.73 Million | -0.503x | +54.02% |
| 2019-12-31 | $111.16 Million | $-121.58 Million | -1.094x | -13.78% |
| 2018-12-31 | $126.24 Million | $-121.36 Million | -0.961x | -219.61% |
| 2017-12-31 | $249.17 Million | $-74.94 Million | -0.301x | -- |
About ADC Therapeutics SA
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatme… Read more